Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

What are Lipids?

What are Lipids?

What are Lipids?

What are Lipids?

Lipids function as structural components of cellular membranes, in addition to acting as energy reservoirs and signaling molecules. They are thus crucial to all living organisms. The three biologically important classes of lipids are triglycerides, phospholipids, and steroids.
Non-Polar and Hydrophobic Characteristics of Lipids
Lipids are a structurally and functionally diverse group of hydrocarbons—compounds consisting of carbon and hydrogen atoms. The carbon-carbon and carbon-hydrogen bonds...

What are Lipids?

What are Lipids?

Lipids function as structural components of cellular membranes, in addition to acting as energy reservoirs and signaling molecules. They are thus crucial to all living organisms. The three biologically important classes of lipids are triglycerides, phospholipids, and steroids.
Non-Polar and Hydrophobic Characteristics of Lipids
Lipids are a structurally and functionally diverse group of hydrocarbons—compounds consisting of carbon and hydrogen atoms. The carbon-carbon and carbon-hydrogen bonds...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).

Diabetic medicine : a journal of the British Diabetic Association·2013

Same author

Thiazolidinediones and fracture risk in patients with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2011

Same author

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Diabetes, obesity & metabolism·2011

Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011

Same author

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010

Same author

Collagen-induced Platelet Activation In Vitro Increases Plasma Catecholamine Concentration.

Platelets·2010

Same journal

Treatment of dyslipidaemias with fluvastatin.

British journal of clinical practice. Supplement·2009

Same journal

Lipoprotein(a) as a marker for coronary heart disease.

British journal of clinical practice. Supplement·2009

Same journal

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.

British journal of clinical practice. Supplement·2009

Same journal

Risk factor management: the cardiologist's perspective.

British journal of clinical practice. Supplement·2009

Same journal

Fluvastatin in combination with other lipid-lowering agents.

British journal of clinical practice. Supplement·2009

Same journal

The patient at risk: who should we be treating?

British journal of clinical practice. Supplement·2009

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Lipid management: past, present, and future.

D J Betteridge¹

¹Middlesex Hospital, London, UK.

British Journal of Clinical Practice. Supplement

|June 4, 2009

Summary

This summary is machine-generated.

Effective lipid disorder management is now possible with HMG-CoA reductase inhibitors, proven to reduce mortality. Widespread screening and treatment of high-risk individuals are crucial for secondary prevention of coronary heart disease.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: Jun 22, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Pharmacology
Public Health

Background:

Lipid disorders pose significant cardiovascular risks.
Therapeutic options for lipid management have advanced considerably.
The 4S study demonstrated mortality benefits of HMG-CoA reductase inhibitors.

Purpose of the Study:

To review the current state of lipid disorder management.
To highlight the impact of HMG-CoA reductase inhibitors.
To emphasize the need for improved screening and treatment implementation.

Main Methods:

Review of therapeutic compounds for lipid disorders.
Analysis of findings from the 4S study.
Discussion of current and future therapeutic targets.

Main Results:

HMG-CoA reductase inhibitors represent a major therapeutic advance.
The 4S study showed a significant reduction in overall mortality.
Implementation of screening and treatment for high-risk individuals remains suboptimal in some regions.

Conclusions:

Clinicians must effectively implement existing knowledge for secondary prevention of coronary heart disease.
Future therapies may target other lipid parameters and the arterial wall.
Continued research into novel compounds and interventions is ongoing.